PharmaShots

FEBRUARY 10, 2023

LEO Pharma Reports P-III Trial (DELTA 2) Results of Delgocitinib for Chronic Hand Eczema Date: Feb 10, 2023 | Tags: LEO Pharma, Delgocitinib, Chronic Hand Eczema, Clinical Trial, P-III, DELTA 2 Trial GSK’s Jemperli (dostarlimab-gxly) Receives the US FDA’s Regular Approval for Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer (..)

FDA 40

FDA 40

PharmaShots

FEBRUARY 10, 2023

LEO Pharma Reports P-III Trial (DELTA 2) Results of Delgocitinib for Chronic Hand Eczema Date: Feb 10, 2023 | Tags: LEO Pharma, Delgocitinib, Chronic Hand Eczema, Clinical Trial, P-III, DELTA 2 Trial GSK’s Jemperli (dostarlimab-gxly) Receives the US FDA’s Regular Approval for Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer (..)

FDA 40

FDA 40

Pharmaceutical Technology

FEBRUARY 10, 2023

This is not the first treatment to come with a high price tag. Their widespread agreements are established in the UK, followed by seven additional countries (Australia, France, Netherlands, Spain, Poland, Italy, and Canada). million, according to GlobalData’s Price Intelligence (POLI), making it the most expensive drug in the world.

FDA 105

FDA 105

Pharmaceutical Technology

JULY 14, 2022

Due to the high price tags associated with these speciality medicines, innovators have naturally favoured big markets with high GDP such as the US and EU-5 (Germany, France, Spain, Italy, and the UK). The choice of where to launch an orphan drug is an important and difficult decision. Europe’s forgotten territories.

Pharmaceutical Companies 59

Pharmaceutical Companies Pharmaceutical Companies Hospitals 59

Pharmaceutical Technology

MAY 2, 2023

High-prescribing physicians surveyed by GlobalData across eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and China) identified a broad range of unmet needs in the IO space (see Figure 1). Despite the significant advances that have been made in the IO field, a huge level of unmet need remains.

Immunization 52

Immunization Vaccines 52

PharmaShots

MARCH 9, 2023

In 2016, she received a special career-recognition award from Fundamed Foundation (a non-profit Spanish foundation) in the category of the most influential pharmaceutical executive from Spain over the past 15 years Education: Belén is an alumnus of the University of Alcala de Henares as an MS, Ph.D., LinkedIn Total experience: 16 yrs.

FDA 40

FDA Pharmaceutical Companies Pharmaceutical Companies Immunization 40

Pharmaceutical Technology

MARCH 17, 2023

In some cases, she said, “[drug] innovation would have been otherwise hindered by their price tag alone”. Watt explained that for newer, first-in-class drugs these types of agreements can also give healthcare systems safety in their decisions to approve certain drugs. Click here to watch this webinar and access the presentation.

Pharmaceutical Companies 102

Pharmaceutical Companies Pharmaceutical Companies Communication 102